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Abstract
The mitochondrial DNA mutation MTTL1 A3243G causes MELAS syndrome (Mitochondrial
Encephalomyopathy, Lactic Acidosis, Stroke-like episodes). The A3243G mutation is also associated
with variable endocrinopathies. We describe 2 case histories of patients with the A3243G mutation. The
first patient presented with diabetes and uncontrolled Graves’ thyrotoxicosis in association with a stroke-
like episode, seizures and cortical blindness. The second patient presented initially with primary
hypothyroidism and vitiligo, and later with glucose intolerance and hypoadrenalism. She went on to
develop the classical features of MELAS syndrome. These cases illustrate the range of endocrine
abnormalities associated with this mitochondrial DNA mutation. MELAS syndrome should be considered
in patients presenting with disparate endocrine conditions in association with neurological problems such
as stroke-like episodes, myoclonic epilepsy, sensorineural deafness and cortical blindness. The
development of thyrotoxicosis or the introduction of thyroid hormone replacement may precipitate a
‘bioenergetic crisis’ by imposing cellular oxidative stress.
Case descriptions
Case 1 A 26-year-old woman presented with a
“stroke-like episode” resulting in left-sided
neglect. She had a background of diabetes
mellitus diagnosed at the age of 22, which was
treated with insulin. A right parietal-occipital
infarct was identified on CT scanning of the
brain. Blood tests at this time showed evidence
of subclinical thyrotoxicosis with free T4 and T3
within normal ranges at 15.1 pmol/l (normal
range 9.0-26.0) and 3.7 pmol/l (normal range
2.5-5.7) respectively, but with undetectable TSH
at <0.05 mU/l (normal range 0.3-4.2).
Her neurological condition subsequently
deteriorated over the course of two months. She
developed cortical blindness, seizures and global
dysphasia. Further investigations showed overt
thyrotoxicosis with free T4 27.2 pmol/l, free T3
7.3 pmol/l, TSH <0.05 mU/l. TSH receptor
antibodies were weakly positive at 2.5 U/ml
(normal range 0-1.5), consistent with a diagnosis
of Graves’ disease. A T2-weighted MRI scan of
the brain showed hyperintensity in the right
parietal-occipital region. Serum and CSF lactate
were elevated (4.4 and 4.3 mmol/l respectively,
NR <1.8). Mitochondrial DNA analysis revealed
an MTTL1 A3243G mutation with heteroplasmy
of 85% in skeletal muscle, 63% in urinary
epithelial cells and 33% in blood. Muscle biopsy
revealed the characteristic changes of MELAS
syndrome (Figure 2). She was commenced on
coenzyme Q10 300 mg tds. Euthyroidism was
restored and maintained with carbimazole 10 mg
daily, and later radioiodine treatment. With this
treatment, her limb weakness, cortical blindness
and left-sided neglect have all improved over 4
years of follow-up.
Case 2 A 23-year-old woman was referred for
evaluation of low body weight and
hypothyroidism. She was diagnosed with
hypothyroidism at age 12 and had been treated
with levothyroxine, but had discontinued
treatment for 6 months prior to assessment.
Examination revealed an under-nourished
woman with normal sexual development,
widespread patches of vitiligo on the hands, a
weight of 28.4 kg, height 1.42 m and BMI of
14.1 kg/m2. Thyroid function tests were
consistent with primary hypothyroidism with
undetectable free T4 of <3.9 pmol/l and TSH of
375 mU/l. Thyroid peroxidase antibodies were
within normal limits at 12 IU/ml (normal <50).
She was re-commenced on levothyroxine and
this was titrated to achieve euthyroid levels with
a maintenance dose of 75 micrograms daily.
With this, she started complaining of frontal
headaches, poor appetite, nausea, vomiting, and
and suffered a further loss of weight. A short
Synacthen test was performed and this revealed
a subnormal cortisol response (baseline 0900h
cortisol 292 nmol/l, peak cortisol 485 nmol/l –
normal peak response >550). Anti-adrenal and
tissue transglutaminase antibodies were both
negative. A 75 g oral glucose tolerance test
showed a fasting plasma glucose of 4.2 mmol/l,
and 2-hour glucose of 8.7 mmol/l. In summary,
investigations revealed a combination of primary
hypothyroidism with vitiligo, a subnormal
cortisol response to Synacthen, and glucose
intolerance.
She was commenced on hydrocortisone
replacement, 20 mg daily in divided doses.
Despite this treatment, her weight loss continued
to a nadir of 24 kg. She developed tonic-clonic
and myoclonic seizures, cortical blindness, and a
deterioration in consciousness. An MRI
scan revealed evidence of bilateral T2
hyperintensity of the cortex and subcortex in the
right temporo-parietal and the left temporo-
occipital lobes (Figure 3). Her serum lactate
levels were elevated at 6.70 mmol/l (normal
range 0.6-2.4). A muscle biopsy revealed the
characteristic changes of MELAS syndrome.
Mitochondrial DNA sequencing revealed the
MTTL1 A3243G mutation in blood with
heteroplasmy of 43%. She was commenced on
coenzyme Q10 200 mg bd and intensive
nutritional supplementation, with nightly enteral
feeding using liquid feed via a percutaneous
gastrostomy. She has had no further seizures and
has gained 13 kg in weight over 9 months of
follow-up.
Discussion
We describe two cases presenting with
endocrine manifestations of the A3243G
mutation in the mitochondrial gene MTTL1, the
mitochondrial tRNA for leucine (UUR). This
gene is encoded in mitochondrial DNA (mtDNA
– Figure 1). In an epidemiologic survey of a
Finnish population of 245,101 individuals, the
frequency of the A3243G mutation was
estimated to be at least 16.3/100,000 (1).
Mutations in mtDNA are maternally inherited as
the zygote inherits mitochondria exclusively
from the oocyte (mitochondria from sperm are
ubiquitinated and degraded). The zygote will
contain a mixture of wild-type and mutant
mtDNA: this is called ‘heteroplasmy’.
Mitochondria are distributed stochastically
between daughter cells during mitosis.
Moreover, mitochondria actively divide, and can
fuse with other mitochondria, leading to the
mixture of mtDNA molecules within each
mitochondrion (2). Lastly, for unknown reasons,
A3243G mutant mtDNA appears to have a
replicative advantage over wild-type mtDNA
(3). Thus, heteroplasmy may vary widely
between different tissues in patients carrying the
A3243G mutation, with the proportion of mutant
mtDNA varying from 3-98% (4).
The A3243G mutation of MTTL1 is manifest in
four main syndromes: (1) classical MELAS
syndrome, as illustrated in the current cases; (2)
maternally-inherited hereditary sensorineural
deafness, diabetes mellitus, ataxia and deafness,
but without stroke-like episodes; (3) progressive
external ophthalmoplegia; and (4) limb
weakness and exercise intolerance (5). The
highly variable clinical presentation, age at
presentation and progression may be due to
differences in the degree of heteroplasmy
between tissues, due to variations in the
threshold levels of mutant mtDNA required to
cause cellular or organ malfunction, and perhaps
due to the influence of the nuclear genome (2).
Disease pathogenesis resulting from the A3243G
mutation is thought to be caused by defects in
mitochondrial function. The mutated
mitochondrial tRNA Leu(UUR) lacks a critical
taurinomethyluridine modification to the third
nucleotide of the tRNA’s anticodon (the so-
called ‘wobble’ position), weakening its ability
to bind the UUG codon. The mutated tRNA also
has a shortened half-life (6, 7). This causes a
translational defect of the ND6 component in the
respiratory chain complex I, which is also
encoded in mtDNA ((8) and Figure 1). As a
result, cells with a higher load of mutant mtDNA
are not able to respire normally (9). Skeletal
muscle, cardiac muscle, and neurons appear to
be most vulnerable, with mitochondrial
dysfunction occurring with mutant mtDNA
loads of 80-90% (10, 11). Furthermore,
mitochondrial dysfunction causes the generation
of reactive oxygen species, which overwhelms
the normal mechanisms for detoxifying these,
so-called ‘mitochondrial oxidative stress’ (12).
Reactive oxygen species cause damage to the
mitochondrial membrane and DNA, and the
release and activation of pro-apoptotic factors,
triggering the activation of the caspase cascade
and apoptotic cell death (13).
The A3243G mutation is associated with
endocrine disease (reviewed in {Stark, 2007
#148}). The most common endocrine
abnormality is diabetes mellitus and glucose
intolerance, as in the cases described here.
Typically, diabetes develops at an early age
(mean age of onset 38), but there is an age-
related increase in penetrance such that
approximately 85% of carriers of the A3243G
mutation develop diabetes or impaired glucose
tolerance by the age of 70 (14). Affected
individuals are lean, require insulin treatment,
but, typically, do not present with ketoacidosis
(15). The pathogenesis of mitochondrial diabetes
has been partially characterized and is thought to
involve a primary beta-cell defect in insulin
secretion and synthesis (16). Part of the problem
is due to impaired coupling of glucose sensing to
insulin secretion: defective mitochondrial
function leads to impaired generation of ATP
from glucose and therefore a lower ATP/ADP
ratio. There is therefore a reduced depolarization
of the beta-cell membrane in response to
glucose, reduced calcium intake and reduced
insulin exocytosis (17). This parallels the
situation in MODY2, in which glucokinase
mutations impair the generation of glucose-6-
phosphate from glucose and cause a non-
progressive defect in glucose-insulin secretion
coupling. Mitochondrial dysfunction also causes
oxidative stress within beta-cells, triggering their
aging and apoptosis. Mitochondrial diabetes is
therefore characterized by a progressive decline
in beta-cell function over time, explaining the
age-related penetrance (14, 18).
Scattered case reports describe other
endocrinopathies associated with mitochondrial
encephalomyopathies. MELAS syndrome can be
associated with GH deficiency (19); deficiencies
in TSH, gonadotrophins and GH (20); and
deficiencies in GH and gonadotrophins (21). The
deficiencies may therefore be isolated or
multiple in nature. Three case reports also
describe hypoparathyroidism in association with
MELAS syndrome (22, 23) and MELAS
combined with Kearns-Sayre syndrome
(progressive ptosis, ophthlamoplegia, myopathy
and pigmentary retinopathy) (24).
MELAS syndrome has also been associated with
thyroid disease in case reports. These include a
case of a woman presenting with features of
Kearns-Sayre syndrome and polyglandular
autoimmune syndrome type 2 manifesting as
primary hypoadrenalism, Type 1 diabetes
mellitus, Hashimoto’s thyroiditis and primary
ovarian failure. The A3243G mutation in this
case was found in association with a large
deletion of mitochondrial DNA (25).
Hyperthyroidism in association with MELAS
syndrome has also been described in two cases
(26, 27).
Thyroid disease itself can influence the
development of MELAS syndrome. It has long
been known that thyroid hormone increases
mitochondrial oxygen consumption, oxidative
phosphorylation, the transcription of
mitochondrial RNA and the expression of
mitochondrial proteins, and the biogenesis of
mitochondria (reviewed in (28)). These effects
are mediated indirectly via nuclear thyroid
receptors and directly via mitochondrial thyroid
receptors (29, 30). Thyrotoxicosis increases
mitochondrial oxidative stress and the
generation of reactive oxygen species, a
phenomenon which underlies the
pathophysiology of thyroid myopathy, and the
deleterious effects of thyrotoxicosis on cardiac
tissue and on the liver (31). Therefore, the
development of thyrotoxicosis in patient 1 may
have been instrumental in precipitating her
neurological crisis, by increasing oxidative
stress and lowering the threshold of
heteroplasmy required to trigger apoptosis. We
also speculate that the deterioration seen in
patient 2 might in a similar fashion have been
triggered by the re-introduction of levothyroxine
treatment for her primary hypothyroidism.
We would therefore suggest that patients with
MELAS syndrome should be monitored for the
development of hyperthyroidism and
aggressively treated, as this may precipitate a
‘bioenergetic crisis’ (32). The introduction of
levothyroxine in the treatment of
hypothyroidism should likewise be carefully
introduced. To protect against the development
of oxidative stress, a combination of
antioxidants, such as coenzyme Q10 and
vitamins C, E and K (33), plus beta-blockade
may be useful. Carvedilol may be an especially
promising agent in this context, as it has alpha
and beta-blocker properties, and as it has been
shown to protect against mitochondrial oxidative
stress in vitro and in vivo (34, 35).
Although the association of MELAS with
diabetes mellitus is well-known, its association
with thyroid, parathyroid, and neuroendocrine
disease is less well-known. The cases described
here underscore the point that this diagnosis
should be considered in patients presenting
insidiously with disparate endocrine conditions,
in association with stroke-like episodes,
myoclonic epilepsy and cortical blindness.
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Figures
Figure 1: Schematic representing human mitochondrial DNA and genes encoded therein. Uncolored
segment indicates the position of the D-loop, the origin of replication for the heavy strand of
mitochondrial DNA. Green segments represent mitochondrial tRNA genes, labeled with the single-letter
IUPAC codes for each amino acid carried by the tRNA (brackets contain the codon bound by the tRNA).
Pink segments represent the mitochondrial ribosomal RNA genes. Orange segments represent the
components of respiratory chain complex I (ND 1-6: NADH dehydrogenase). Blue segments represent the
components of respiratory chain complex IV (CO I-III: cytochrome c oxidase). Red segments represent
the components of respiratory chain complex V (ATPase 6,8: ATP synthase). Yellow segment represents
the component of respiratory chain complex III (Cytb: cytochrome b). The position of MTTL1, encoding
the mitochondrial tRNA for Leu(UUR) is indicated by the arrow.
Figure 2: Skeletal muscle biopsy of patient 1 shows abnormal muscle fibers with haematoxylin and eosin
stain (arrow, top left panel) and "ragged blue fibers" with a histochemical stain for succinate
dehydrogenase (SDH), which stains mitochondria, thus demonstrating mitochondrial proliferation (arrow,
top right panel). Cytochrome c oxidase (COX) staining shows marked heterogeneity (bottom left panel).
An additional feature is overabundance of mitochondria in smooth muscle and endothelial cells of
intramuscular blood vessels on SDH staining (arrow, bottom right panel).
Figure 3: MRI scan of patient 2, showing bilateral T2 hyperintensity of the cortex and subcortex in the
right temporo-parietal and the left temporo-occipital lobes.
